• Home
  • News
    • Pre-Meeting
    • Meeting Coverage
    • Post-Meeting
    • Poster Presenters 2024
    • Archives
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
  • Map & Photos
  • Industry
    • Industry Events
      • Featured Industry Events
      • Innovation Theaters
      • Industry-Supported Symposia
      • Lightning Talks
    • Industry Connections
  • Publications
    • Preview Edition Newspaper
    • Meeting Magazine
  • App & Planner
  • Schedule
  • Resources
    • App & Planner
    • Schedule
  • Follow Us
    • X (Twitter)
    • Facebook
    • LinkedIn
    • YouTube
  • Subscribe
Meeting Home

The official news source of ACR Convergence 2024

Watch On Demand
  • Outlook for treating metabolic bone disease improves

    Outlook for treating metabolic bone disease improves

    November 10, 2019

    Approaches and treatments for the metabolic bone disorders rheumatologists are most likely to see, hypophosphatasia, osteomalacia, and primary hyperthyroidism, are changing, and the outlook on all three is improving.

  • Monoclonal gammopathy’s 
spectrum of severity makes 
clinical decision-making difficult

    Monoclonal gammopathy’s 
spectrum of severity makes 
clinical decision-making difficult

    November 10, 2019

    S. Vincent Rajkumar, MD, Professor of Medicine at the Mayo Clinic, Rochester, Minnesota, said that the significant prevalence of monoclonal gammopathies and their association with a variety of conditions, including multiple myeloma, make this topic important for clinicians.

  • Research attempts to clarify concepts of 
incomplete lupus and low disease activity

    Research attempts to clarify concepts of 
incomplete lupus and low disease activity

    November 10, 2019

    The session will include discussion of the development of the new classification criteria for lupus, including the concept of “incomplete lupus” as it pertains to identifying patients who may not meet all of the classification criteria.

  • Wnt signaling pathway could lead to breakthrough treatments in OA

    Wnt signaling pathway could lead to breakthrough treatments in OA

    November 10, 2019

    Wnt signaling pathway research that is moving toward early stage clinical trials could provide the first disease modifying treatments for OA.

  • As inflammasome knowledge expands, so do potential areas for treatment

    As inflammasome knowledge expands, so do potential areas for treatment

    November 10, 2019

    Two researchers who have contributed greatly to understanding the role of the inflammasome and cytokines will share their knowledge Tuesday morning during a Basic Science session.

  • Learn about extrafollicular T helper cells to understand more about biology of lupus

    Learn about extrafollicular T helper cells to understand more about biology of lupus

    November 10, 2019

    Recent research shows that Tfh cells are not the only players in T cell/B cell interactions leading to autoimmune disease. There are also populations of extrafollicular T helper cells that can affect T cell/B cell interactions.

  • Multiple new treatments add complexity to selecting the best psoriatic arthritis treatment for each patient

    Multiple new treatments add complexity to selecting the best psoriatic arthritis treatment for each patient

    November 10, 2019

    M. Elaine Husni, MD, MPH, Vice Chair of the Department of Rheumatic & Immunologic Diseases at the Cleveland Clinic, Ohio, said given the number of new therapeutics available for PsA, it’s important for rheumatologists to become familiar with the new options in terms of mechanisms…

  • Expert panel to weigh in on 
key RA treatment questions

    Expert panel to weigh in on 
key RA treatment questions

    November 10, 2019

    Gordon Starkebaum, MD, said the session’s goal was to cover useful information and also to engender discussion. The audience will be able to submit questions for the expert panel during the session.

  • Immunology Update session to feature closer look at anifrolumab for lupus treatment

    Immunology Update session to feature closer look at anifrolumab for lupus treatment

    November 10, 2019

    At different stages in research, type 1 interferon (IFN) has been identified as a causal factor in lupus, a biomarker, and a potential therapeutic target. IFN can play all three roles, but recently there has been much debate about whether IFN is a therapeutic target.

  • Education experts to offer strategies for effective teaching

    Education experts to offer strategies for effective teaching

    November 10, 2019

    Students of all ages and levels rely on high-quality feedback to improve their knowledge and skills — making the delivery of effective, real-time feedback.

Previous Page
1 … 3 4 5 6 7 … 12
Next Page

Upcoming Featured Industry Events

View All

View Archives

  • Select Year
    • 2017
    • 2018
    • 2019
    • 2020
    • 2021
    • 2022
    • 2023

Popular Articles

  • Daltroy Lecture Examines the Psychological Impacts of Living with Rheumatic Disease


  • ARP Distinguished Lecture: Better Understanding of AI Will Enhance Its Utility for Rheumatologists


  • FDA Gives Updates on Newly Approved Agents for Rheumatic Diseases


  • Clinicians Discuss Experience Using Ambient Listening Technology in Clinical Practice


  • Opening Session Keynote Spotlights the Crucial Role of Allyship in Rheumatology



@2024 American College of Rheumatology. All Rights Reserved. Powered by TriStar Event Media, LLC

Privacy Policy